Benjamin Halladay, Chief Financial Officer at Esperion Therapeutics, sold ESPR on Jun 17, 2026
Prices as of Jul 13 · price update delayed · Every feed →
▼ SELL$34K10,773 shares at $3.15Benjamin Halladay Chief Financial OfficerESPR Esperion Therapeutics, Inc.
- Traded
- Jun 17, 2026
- Disclosed
- Jun 18, 2026
- Filed
- 1 day after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
ESPR since disclosure
+1.0%
after the sale
Similar stocks (XLV) since disclosure
+8.0%
XLV — its sector index fund
Change in closing price from Jun 18, 2026 (the first trading day on or after disclosure) to Jul 13, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.